New data from the Phase III BouNDless trial and its ongoing open-label extension (OLE) support the long-term efficacy of ND0612 in people with Parkinson’s disease (PD) experiencing motor fluctuations.

The new clinical trial data was shared at the 2024 International Congress of Parkinson’s Disease and Movement Disorders (MDS).

ND0612 is being studied as a 24-hour, continuous, subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD).

The data highlight one-year outcomes from the BouNDless-OLE phase that are consistent with previously-reported 12-week data from the study evaluating the long-term efficacy of ND0612.

Additional presentations discussed findings from patient-reported outcomes favouring ND0612 vs. oral immediate-release (IR) LD/CD across various measures of quality of life (QoL) and the effect of treatment on motor signs and motor experiences of daily living (m-EDL).

“The longer-term data presented at MDS provide insights into the potential of ND0612 to not only improve symptoms, but also maintain its efficacy, which may provide patients with a meaningful reduction in symptom burden,” said Gustavo Suarez Zambrano, Vice President of Medical Affairs at Mitsubishi Tanabe Pharma America (MTPA). “These findings reinforce our commitment to studying ND0612, if approved, as a potential new treatment option for people with PD experiencing motor fluctuations, as well as ensuring the latest scientific knowledge is continuously shared with the community.”

ND0612 is an investigational drug-device combination therapy – a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with PD.

Development of the combination therapy is being led by NeuroDerm, a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC).

Diana Spencer, Senior Digital Content Editor, DDW